TP53 and neoplasm: Other examples of such an approach can be found in the study by Kamran et al., (2019) that in a small set of well-studied LARC, treated with nCRT demonstrated that concurrent KRAS/TP53 mutations were associated with a non-responder tumor phenotype and were enriched for an epithelial–mesenchymal transition transcriptional profile.